News of the Day

The biggest community run in Western Australia will return after a three-year 'pandemic' hiatus with around 35,000 people expected to participate.

Almost one in ten residents in Australian Aged Care homes are continuing to lose weight, when they should not, according to the latest data released by the Australian Institute of Health and Welfare.

Private Healthcare Australia says the current second-tier default policy needs to be reformed because it is not meeting its intended purpose of supporting smaller hospitals and hospitals in under-serviced areas.

Australian biotechnology company PharmAust (ASX:PAA) has announced that the first patient has been dosed in its Phase 1/2 clinical trial testing the effects of its monepantel in people living with motor neurone disease.

“The expanded listing of OPDIVO is vitally important. It will provide affordable treatment that will improve the lives of patients with gastro-oesophageal cancers," said health minister Mark Butler.

The first 'Week in Review' episode of 'The Dispatched Podcast' discusses the ongoing dispute over the implementation of the new PBS pricing framework, the 'Halton review' of Australia's COVID-19 vaccine and treatment procurement planning, and the significant implications of the new national anti-corruption commission.

The TGA has provisionally approved Pfizer's COVID-19 vaccine, COMIRNATY, for use in children aged 6 months to under 5 years old.

During her 14 years as a Federal Court Judge, Justice Jayne Jagot delivered judgements on a range of high-profile cases involving pharmaceutical companies, including patent disputes.

Ipsen has welcomed the listing on the PBS of the first treatment for children with an extremely rare growth deficiency.

Rare Cancers Australia CEO, Richard Vines, said, “This is welcome news for Australians living with MDS and CMML. It not only means that the financial weight is lifted, it means that patients will have the opportunity to lead more independent, productive lives."

The new anti-corruption body will define corrupt conduct as the misuse of confidential information, advantaging one stakeholder over others, abusing power through threats and coercion, dishonesty and breaching public trust.

Just over four weeks until the BioPharmaDispatch 'Post-Budget Summit' that will be held at a critical time for the biopharmaceutical sector and in the period immediately following the Labor government's first Budget.